• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Latest News

New advances in epilepsy: highlights from AES 2024

December 17, 2024  

SPECIAL REPORT

AI model predictive of ASM response
Perampanel – PORTABLE study results
Cenobamate mechanism of action
New data for adjunctive cenobamate: three studies
Failed trial of soticlesat in Lennox-Gastaut syndrome (LGS)

Read More

TOPICS: AES 2024, EPILEPSY

Fluid biomarkers in MS – the year in review

November 25, 2024  

SPECIAL REPORT

NfL
GFAP
CHIT1

Read More

TOPICS: BIOMARKERS IN MS

High-efficacy DMTs in MS – the year in review

November 14, 2024  

SPECIAL REPORT

Intensive therapy vs. escalation
Long-term data
B cell depletion and EBV
New formulation
Treatment discontinuation

Read More

TOPICS: MS

Cenobamate as adjunctive therapy for partial-onset seizures: a review

October 25, 2024  

SPECIAL REPORT

Mechanism of action
Efficacy and safety studies
Use of adjunctive cenobamate in practice

Quick poll on epilepsy management
Submit your answers to reveal how your colleagues voted (respondents remain anonymous)

Read More

TOPICS: EPILEPSY
Previous
13
14
15
16
17
Next

Browse by Topic

  • CLINICAL CASES (21)
  • MS (439)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Ultomiris (ravulizumab) now publicly reimbursed in gMG posted on April 7, 2026
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions